期刊
SUBSTANCE ABUSE
卷 42, 期 2, 页码 153-157出版社
SAGE PUBLICATIONS INC
DOI: 10.1080/08897077.2021.1903659
关键词
Buprenorphine; quality of care; access to care; policy; DATA 2000
资金
- National Institute on Drug Abuse [R01DA045800-01, K01DA042139]
- Florida Supreme Court Office of the State Courts Administrator
- National Institute on Drug Abuse [NIH/NIDA] [1UG1DA049444-01]
Buprenorphine is a gold standard medication for treating opioid use disorder, proven to prevent overdose and improve quality of life. The X-waiver allowing clinicians to prescribe buprenorphine in office-based settings is expected to be repealed in the United States, necessitating various strategies to establish a new treatment system.
Buprenorphine is one of the gold standard medication treatments for opioid use disorder (OUD), with proven effectiveness in preventing overdose, increasing abstinence, and improving quality of life. In the United States, buprenorphine can be legally prescribed and administered in office-based settings from clinicians who are specially credentialed to provide that care under the X-waiver. We believe the X-waiver will ultimately be repealed, but there is a need for a variety of strategies to create a new treatment system after the X-waiver. Building a new tier of treatment capacity will require educational outreach, systems strategies, and enhanced payments.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据